Compare Advanced Micro Devices (AMD) vs AstraZeneca plc (AZN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Advanced Micro Devices vs AstraZeneca plc — how do they compare? Advanced Micro Devices trades at $545.85 (market cap $909.70B), while AstraZeneca plc trades at $169.7 (market cap $262.75B). The key difference: Advanced Micro Devices is far larger — about 3.5× AstraZeneca plc's market cap, and AstraZeneca plc pays a 1.84% dividend while Advanced Micro Devices pays none. Which is the better fit depends on your goals.
| AMD | AZN | |
|---|---|---|
Market Cap | $909.70B | $262.75B |
Sector | Technology | Health |
52-Week High | $580.91 | $209.48 |
52-Week Low | $146.24 | $137.44 |
Enterprise Value | $901.22B | $289.00B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD trades at $557.89, up 2.04% today, approaching its 52-week high amid strong AI-driven momentum. The stock shows bullish technical signals with consistent earnings beats and robust revenue growth, reaching $34.64B in 2025. Analyst sentiment remains overwhelmingly positive with a 71.43% buy rating, though valuation metrics like a P/E of 185.96 indicate premium pricing. Cash flow from operations surged to $7.71B in 2025, supporting aggressive investment in AI infrastructure.
Outlook: AMD is well-positioned to capitalize on AI and data center demand, but high valuation and intense competition pose risks. Investors should weigh growth potential against premium multiples, with the consensus price target of $508.24 suggesting near-term caution despite long-term optimism.
AstraZeneca (AZN) trades at $171.61, down 3.85% following a Phase 3 clinical trial failure for its Wainua heart drug. The stock faces bearish technical signals with support at $167 and resistance at $177. Fundamentally, the company maintains strong profitability with 17.19% net margins and robust revenue growth, reaching $58.74B in 2025. Analyst consensus remains positive with 47.5% buy ratings despite recent setbacks.
The outlook remains cautiously optimistic as AstraZeneca's core business fundamentals remain intact with improving cash flow and debt reduction. However, pipeline execution risks and clinical trial uncertainties present near-term headwinds. Long-term investors may find value at current levels given the company's strong market position and financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
